# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Roald Amundsen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX003-SYN-TD
- Date: 1928-03-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ingrid Solheim-Achebe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review of finger pain on capsaicin cream. **S**

## History of present illness

Mr. Amundsen returns four weeks after starting capsaicin cream. It stung for the first week and he has used it about three times a day. The burning is a little less, but the cold attacks still come most days in the late winter weather, and his average pain over the past week is 5 of 10. He still wakes some nights. He is willing now to try a tablet if it will not make him drowsy, because he drives and expects to fly again. He drinks rarely and takes no other medicines. **S**

| Element | Detail |
|---|---|
| Finger pain | Average 5 of 10 over the past week |
| Capsaicin cream | About three times a day; stinging in the first week |
| Sleep | Still woken some nights |
| Preference | Will try a tablet that does not cause drowsiness |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Burning and numbness of the fingers with cold, slightly less |
| Integumentary | Negative | No skin irritation now; no finger ulcers |
| Psychiatric | Negative | Mood fair |

3 systems reviewed. **S**

## Current medications

- Capsaicin 0.075% cream, a small amount rubbed into the painful fingers four times a day; wash hands after use and keep away from the eyes **S**
- Duloxetine 30 mg delayed-release capsule, one capsule by mouth daily for one week **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 79 kg; BMI 23.6 kg/m². All vital signs are synthetic.

Finger pain, 0 to 10: 5. All results are synthetic.

## Change since baseline

- Finger pain, 0 to 10: 6 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 62, weight 79.0 kg |
| Hands | Fingertips cool; skin intact; no redness from the cream |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Post-frostbite neuropathic pain of the fingers, partly controlled** (M79.2). Average pain down from 6 to 5 of 10 on capsaicin cream; not enough. Of the first-line oral drugs in NICE CG173 (amitriptyline, duloxetine, gabapentin, pregabalin), duloxetine is chosen because it is the least likely to cause drowsiness, which matters for driving and flying, and because it has no anticholinergic effects. Blood pressure 126/78 before starting. **S**
   - Duloxetine 30 mg daily for a week, then 60 mg daily; take with food.
   - Continue capsaicin cream if it helps.
   - Do not take tramadol or other serotonergic medicines; ask before any new medicine.
   - Do not stop duloxetine suddenly.
   - Sodium and ALT in two to four weeks.
   - Review in about six weeks; the preventive visit in two weeks will also check how he is tolerating it.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Pain severity (0 to 10 numeric rating) and overall improvement | Every review, and early after starting or changing a medicine | Completed today | Average 5 of 10, from 6 |
| Medication safety | Adverse effects, especially drowsiness, dizziness and nausea | Every review, and early after starting or changing a medicine | Completed today | Stinging from capsaicin in the first week only; duloxetine started today |
| Examination | Daily activities and participation: fine hand tasks in the cold, driving, flying | Every review, and early after starting or changing a medicine | Completed today | Still fumbling outdoors; driving safely |
| Survey | Mood (PHQ-9) and anxiety | Every review, and early after starting or changing a medicine | Completed today | Mood fair by interview; PHQ-9 due at the next review |
| Examination | Sleep quality | Every review, and early after starting or changing a medicine | Completed today | Woken some nights |
| Examination | Blood pressure | Before starting duloxetine and periodically on it | Completed today | 126/78 mmHg before starting duloxetine |
| Laboratory | Sodium and liver enzyme (ALT) on duloxetine | Baseline, then once in the first weeks of treatment | Ordered | Baseline at intake (sodium 141 mmol/L, ALT 24 U/L); repeat ordered for two to four weeks after starting |
| Medication safety | Interactions: no tramadol or other serotonergic drugs; caution with oral NSAIDs; alcohol | When starting, then every review | Completed today | No tramadol or other serotonergic drugs; rare alcohol |
| Self-management | Skin of the fingers and cold protection | Every review, and early after starting or changing a medicine | Completed today | Skin intact; cold protection continued |

## Goal progress

- Average finger pain at or below 3 of 10, with fewer cold attacks, by four months. In progress; target 1928-06-09. **S**
- Able to handle buttons, keys and a pen outdoors in the cold with protective gloves. In progress; target 1928-05-05. **S**
- Any medicine used causes no daytime drowsiness that affects driving or flying. In progress; target 1928-06-09. **S**

## Medication changes

- Started: Duloxetine 30 mg delayed-release capsule, one capsule by mouth daily for one week **S**

## Guideline basis

- Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173) (2013, updated 2020), National Institute for Health and Care Excellence
- Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update (McIntosh SE, et al. Wilderness Environ Med 2024;35(2):183-197) (2024), Wilderness Medical Society

## Follow-up

- Preventive visit in two weeks. Neuropathic pain review in six weeks. **S**
- Next scheduled visit 1928-04-07: periodic adult preventive visit. **S**
